Resource Development Core

ABSTRACT - RESOURCE DEVELOPMENT CORE (RDC) The main goal of the University of Michigan O'Brien Kidney Translational Resource Center (MKTC) is to provide an effective translational research pipeline that relies on a systems biology approach to develop novel, diagnostic, prognostic and therapeutic strategies for patients with kidney diseases. Our Resource

Development Core (RDC) will support the Applied Systems Biology Core (ASBC), the Data Analytic Services Core (DASC) and the kidney research community at large by developing a unified platform and methods that integrate multidimensional data, cohort selection and clinical trial design. The University of Michigan Precision

Health Initiative (PHI), which incorporates all data from Michigan Medicine patients in addition to social determinants of health and biological samples, represents a unique resource that the RDC will expand upon to develop the following pipelines: a. Biomarker candidate selection, assay, validation, and incorporation into study design. The RDC will

establish a database and pipeline to provide investigators the most promising biomarkers, relevant assays based on the outcomes investigated, in addition to guidance surrounding validation and quality control. b. Cohort development. We will leverage the infrastructure of the PHI to build algorithms to identify and curate

with high confidence kidney-specific diagnoses, relevant clinical characteristics, laboratory testing, social determinants of health, well as outcomes through integrating multiple data sources including billing codes and natural language processing. The end-result will provide investigators the ability to easily identify relevant

cohorts and rapidly retrieve data in a format that is ready to analyze through a graphical user interface. c. Kidney outcomes. We will establish a pipeline to incorporate United States Renal Data System (USRDS) data into the PHI platform, enriching the Michigan Medicine dataset and providing confirmatory data for cohort-

specific analyses. d. Novel metabolomic technologies and multi-omic integration. In addition to developing spatial metabolomic platform, we improve tools for annotation of untargeted metabolomics data and identification of new compounds and provide novel integrative analysis of metabolomics-proteomics-transcriptomics- epigenomics

data. e. Clinical trial design. We will establish a workflow for kidney-specific clinical trial design and implementation, as well as provide associated workshops through the highly successful Clinical Trials Academy. The pipelines and workflows to be established by the RDC will provide investigators across the spectrum of

research stages – from bench (biomarker discovery) to bedside (clinical trial design) – the ability to integrate of multidimensional data – from social determinants of health to organic biomarkers and outcomes – in addressing the major challenges the management of patients with kidney disease.